Cargando…
The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function
Leflunomide, a potent disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis (RA), exhibits anti-inflammatory, antiproliferative and immunosuppressive effects. Although most of the beneficial effects of leflunomide have been attributed to its antimetabolite activity, main...
Autores principales: | Kirsch, Bernhard M, Zeyda, Maximilian, Stuhlmeier, Karl, Grisar, Johannes, Smolen, Josef S, Watschinger, Bruno, Stulnig, Thomas M, Hörl, Walter H, Zlabinger, Gerhard J, Säemann, Marcus D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1174963/ https://www.ncbi.nlm.nih.gov/pubmed/15899055 http://dx.doi.org/10.1186/ar1727 |
Ejemplares similares
-
The active metabolite of leflunomide, A77-1726, increases proliferation of human synovial fibroblasts in presence of IL-1β
por: Magne, D, et al.
Publicado: (2004) -
Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels
por: Fajardo-Robledo, Nicte S., et al.
Publicado: (2022) -
The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes
por: Palmer, Gaby, et al.
Publicado: (2004) -
The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1
por: Moon, Su-Jin, et al.
Publicado: (2017) -
Leflunomide leads to inhibition of transendothelial migration
por: Grisar, J, et al.
Publicado: (2001)